NASDAQ:MGTA - Magenta Therapeutics Stock Price, Forecast & News

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Magenta Therapeutics Inc (NASDAQ:MGTA) posted its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.00. View Magenta Therapeutics' Earnings History.

Magenta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Magenta Therapeutics.

5 equities research analysts have issued 12-month price objectives for Magenta Therapeutics' shares. Their forecasts range from $18.00 to $22.00. On average, they expect Magenta Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 46.1% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.

News articles about MGTA stock have trended somewhat negative this week, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Magenta Therapeutics.

Some companies that are related to Magenta Therapeutics include Aurinia Pharmaceuticals (AUPH), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Aimmune Therapeutics (AIMT), Prestige Consumer Healthcare (PBH), Cambrex (CBM), Ironwood Pharmaceuticals (IRWD), Principia Biopharma (PRNB), Xencor (XNCR), Pacira Biosciences (PCRX), Zymeworks (ZYME), Akcea Therapeutics (AKCA), Insmed (INSM), Forty Seven (FTSV) and Arvinas (ARVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Cidara Therapeutics (CDTX), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), Tetraphase Pharmaceuticals (TTPH), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Concert Pharmaceuticals (CNCE) and Corbus Pharmaceuticals (CRBP).

(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGTA stock can currently be purchased for approximately $13.69.

Magenta Therapeutics has a market capitalization of $533.77 million. The company earns $-57,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.View Additional Information About Magenta Therapeutics.

The official website for Magenta Therapeutics is http://www.magentatx.com/.

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]